Evidence map›Paper›PMID 7710947›Full record

ArticleBritish journal of cancer1995

Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.

K Pryor, J Goddard, D Goldstein, P Stricker, P Russell, D Golovsky, R Penny

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Review
  2. Review of BCG immunotherapy for bladder cancer.Clinical microbiology reviews · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

K PryorCentre for Immunology, St Vincent's Hospital, Sydney, NSW, Australia.
J Goddard
D Goldstein
P Stricker
P Russell
D Golovsky
R Penny

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A cytotoxicity assay was used to study the action of bacillus Calmette-Guerin (BCG) and cytokines on four human bladder cancer cell lines. Monocytes and lymphocytes from peripheral blood were incubated with or without BCG or cytokines for 24 h, after which [3H]thymidine-labelled target cells were added and the 72 h percentage specific release determined. BCG had a direct cytotoxic effect against tumour cells and significantly enhanced monocyte/macrophage and enhanced lymphocyte cytotoxicity against one cell line (UCRU-BL-17). Supernatants (SNs) from BCG-activated monocytes/macrophages and lymphocytes increased the percentage specific release of [3H]thymidine from UCRU-BL-17 cells. Interferon alpha (IFN-alpha) and interleukin 2 (IL-2) were cytotoxic towards UCRU-BL-17. No synergy occurred between BCG and cytokines at the concentrations tested. The results suggest that BCG is superior to IFN-alpha, interferon gamma (IFN-gamma) and IL-2 in enhancing cell-mediated cytotoxicity.

Indexed as

Carcinoma, Transitional CellCell LineCytotoxicity, ImmunologicHumansInterferon-alphaInterferon alpha-2Interferon-gammaInterleukin-2LymphocytesMacrophagesMonocytesMycobacterium bovisRecombinant ProteinsT-LymphocytesTumor Cells, CulturedUrinary Bladder NeoplasmsInterferon-alphaInterferon alpha-2Interferon-gammaInterleukin-2Recombinant Proteins

Identifiers

PMID7710947
PMCPMC2033737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.